Anthrax News and Research

RSS
Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.

Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.

Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
Lysozyme can protect anthrax contamination in processed foods: Study

Lysozyme can protect anthrax contamination in processed foods: Study

Doctoral students receive insights on potential career paths at symposium hosted by Emergent Biosolutions

Doctoral students receive insights on potential career paths at symposium hosted by Emergent Biosolutions

Advanced Life Sciences seeks government funding for development of Restanza antibiotic

Advanced Life Sciences seeks government funding for development of Restanza antibiotic

Cangene to focus commercialization efforts on key markets

Cangene to focus commercialization efforts on key markets

Emergent BioSolutions enters agreement to acquire Trubion Pharmaceuticals

Emergent BioSolutions enters agreement to acquire Trubion Pharmaceuticals

Aradigm reports net loss of $4.1M for second-quarter 2010

Aradigm reports net loss of $4.1M for second-quarter 2010

TLV, Emergent BioSolutions form joint venture to develop broad spectrum pandemic flu vaccine

TLV, Emergent BioSolutions form joint venture to develop broad spectrum pandemic flu vaccine

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

Advanced Life Sciences reaches SPA agreement with FDA for Restanza Phase 3 study

Advanced Life Sciences reaches SPA agreement with FDA for Restanza Phase 3 study

Response Biomedical second-quarter revenue from product sales increases 2%

Response Biomedical second-quarter revenue from product sales increases 2%

Elusys awarded second contract to develop Anthim for treatment of anthrax infection

Elusys awarded second contract to develop Anthim for treatment of anthrax infection

Prairie dog study holds significant implications for understanding spread of infectious diseases

Prairie dog study holds significant implications for understanding spread of infectious diseases

BARDA awards contract to develop Pfenex Expression Technology

BARDA awards contract to develop Pfenex Expression Technology

Response Biomedical closes $8 million common share private placement

Response Biomedical closes $8 million common share private placement

Response Biomedical announces shareholder approval for $8 million private placement

Response Biomedical announces shareholder approval for $8 million private placement

Advanced Life Sciences enters agreement with UBC to develop antimicrobial peptides

Advanced Life Sciences enters agreement with UBC to develop antimicrobial peptides

Advanced Life Sciences enters debt for equity exchange agreement with CEO

Advanced Life Sciences enters debt for equity exchange agreement with CEO

Cangene eliminated from ARS contract

Cangene eliminated from ARS contract

Lyophilized rPA anthrax vaccine more immunogenic than liquid formulation: Study

Lyophilized rPA anthrax vaccine more immunogenic than liquid formulation: Study

Elusys, Lonza partner for commercial production of Anthim antibody for inhaled anthrax treatment

Elusys, Lonza partner for commercial production of Anthim antibody for inhaled anthrax treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.